EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study

Giovanni Novi iD, Francesca Bovis iD, Chiara Sciolla, Jessica Frau, Matteo Minetti, Francesca Napoli, Marika Vianello, Giacomo Greco, Elia Sechi, Andrea Bellomo, Paola Garelli, Antonio Luca Spiezia und 22 weitere

CNS Drugs · 2025

DOI: 10.1007/s40263-025-01191-7 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift CNS Drugs, 2025. Verfasst von Giovanni Novi und 33 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Ospedale Policlinico San Martino, Genoa, Italy. giovanninovi@gmail.com. Hauptthemen laut MEDLINE: Rituximab, Neuromyelitis Optica, Immunologic Factors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Multiple Sclerosis Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a severely disabling autoimmune disease that predominantly impacts the optic nerves and spinal cord. It is often linked to immunoglobulin G (IgG) antibodies targeting the aquaporin-4 water channel (AQP4-IgG). Rituximab, which depletes CD20-positive B cells, is effective in reducing the frequency of NMOSD relapses. The objective of this retrospective, 5-year observational study was to evaluate the effectiveness and safety of rituximab in patients with AQP4-IgG-positive NMOSD. METHODS: We conducted a multicenter, retrospective study using prospectively collected data from 23 multiple sclerosis (MS) and NMOSD centers (22 in Italy, 1 in Switzerland). The study cohort included patients with AQP4-IgG-positive NMOSD who had completed rituximab induction therapy, with data collected up to May 2024. Two maintenance strategies were used-fixed 6-monthly infusions or reinfusions guided by flow cytometry-on the basis of CD19+ or CD27+ memory B-cell repopulation thresholds. Clinical outcomes included annualized relapse rate (ARR), time to first relapse (TTFR), and Expanded Disability Status Scale (EDSS) worsening, which was assessed both overall and between relapses to indirectly evaluate the possibility of inter-attack disability progression. Safety outcomes encompassed infusion-related reactions and adverse events. RESULTS: A total of 138 patients were analyzed. ARR significantly decreased from 1.54 (95% confidence interval (CI) 1.34-1.75) before rituximab to 0.15 (95% CI 0.12-0.19) over the 5-year follow-up. Approximately 33% of patients experienced at least one relapse during treatment, after a median time of 5.21 months. Higher pre-rituximab relapse rates were associated with shorter TTFR. Subtle increases of 0.5-1 points in EDSS between relapses were observed in one third of patients. Mild infections were common, and 21% of patients experienced infusion-related reactions. In addition, six patients developed malignancies. CONCLUSIONS: Over 5 years, rituximab consistently reduced the incidence of relapses in patients with NMOSD, though 33% of them still experienced a relapse during this period, generally within the first 6 months of treatment. No unexpected adverse events were identified. While safety monitoring remains crucial, further studies are needed to better understand rituximab's impact on NMOSD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabNeuromyelitis OpticaImmunologic FactorsHumansFemaleMaleAdultRetrospective StudiesMiddle AgedAquaporin 4Treatment OutcomeRecurrenceItaly

Substanzen

RituximabImmunologic FactorsAquaporin 4AQP4 protein, human

Autor:innen und Institutionen

  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy. giovanninovi@gmail.com.
  • Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Reg. Gonzole 10, Orbassano, 10043, Turin, Italy.
  • Multiple Sclerosis Centre, ASL Cagliari, Cagliari, Italy.
  • Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Multiple Sclerosis Clinical and Research Unit, Department of System Medicine, Tor Vergata University, Rome, Italy.

ORCID-Profile: Giovanni Novi, Francesca Bovis

Förderung

  • National Multiple Sclerosis Society

Zitieren

APA

Novi, G., Bovis, F., Sciolla, C., Frau, J., Minetti, M., Napoli, F., Vianello, M., Greco, G., Sechi, E., Bellomo, A., Garelli, P., Spiezia, A. L., Fantozzi, R., Schirò, G., Ghezzi, L., Zecca, C., Signoriello, E., Brambilla, L., Lucchini, M., …, & Sormani, M. P. (2025). Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study. CNS Drugs. https://doi.org/10.1007/s40263-025-01191-7

Vancouver

Novi G, Bovis F, Sciolla C, Frau J, Minetti M, Napoli F, et al. Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study. CNS Drugs. 2025. doi:10.1007/s40263-025-01191-7

BibTeX
@article{Novi2025,
  author = {Novi, Giovanni and Bovis, Francesca and Sciolla, Chiara and Frau, Jessica and Minetti, Matteo and Napoli, Francesca and Vianello, Marika and Greco, Giacomo and Sechi, Elia and Bellomo, Andrea and Garelli, Paola and Spiezia, Antonio Luca and Fantozzi, Roberta and Schirò, Giuseppe and Ghezzi, Laura and Zecca, Chiara and Signoriello, Elisabetta and Brambilla, Laura and Lucchini, Matteo and Bonavita, Simona and Schiavetti, Irene and Malentacchi, Maria and Cocco, Eleonora and Franceschini, Alessandro and Mataluni, Giorgia and Gastaldi, Matteo and Rolando, Anna and Solla, Paolo and Cellerino, Maria and Abbadessa, Gianmarco and Lanzillo, Roberta and Di Sapio, Alessia and Uccelli, Antonio and Sormani, Maria Pia},
  title = {Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study},
  journal = {CNS Drugs},
  year = {2025},
  doi = {10.1007/s40263-025-01191-7}
}
Kostenlos starten →